HealthlineWeight Loss Surgeries Decline as GLP-1 Use Skyrockets. Why This Matters

ℹ️ Observational Association Only Evidence
Researchers analyzed national bariatric surgery registry data from 2020 to 2024 and presented findings at the ASMBS Annual Meeting. Total bariatric procedures peaked in 2022 then declined, with sleeve gastrectomy share decreasing and Roux-en-Y conversions increasing.

Clinical Considerations

• Findings were presented at a conference and have not yet undergone peer review
• Sleeve gastrectomy remains the most performed bariatric procedure despite its declining share
• Roux-en-Y gastric bypass conversions are rising, often performed after initial sleeve gastrectomy for inadequate response or complications
• Long-term comparative effectiveness data for GLP-1 therapy versus surgery in severe obesity (BMI 35+ with comorbidities) is still maturing
• Surgical specialists caution against patients with severe obesity defaulting to GLP-1s without informed comparison of long-term effectiveness data

Practice Applications

• Recognize that GLP-1 therapy and bariatric surgery are not interchangeable across all obesity severities
• Consider surgical referral for patients with BMI 35+ with serious comorbidities, even when GLP-1 therapy is available
• Integrate shared decision-making conversations covering medication adherence durability, surgical risk, and long-term outcomes
• Monitor patients on GLP-1 monotherapy for sustained response and discuss next steps if response is inadequate
• Avoid framing either modality as universally superior without considering the individual clinical picture